ARK Investment Management Adds $42M in GeneDx Holdings Corp. ($WGS)

ARK Investment Management has boosted its position in GeneDx Holdings Corp. (NasdaqGS: WGS) by a substantial 119%. According to the latest Form 13F filing with the SEC, ARK added 720,022 shares, bringing its total holdings to 1,324,583 shares valued at approximately $80.3 million. This reflects ARK's increased confidence in GeneDx's prospects as of the reporting period.

What Changed in ARK Investment Management's GeneDx Holdings Position

ARK Investment Management significantly increased its stake in GeneDx Holdings, moving from 604,561 shares to 1,324,583 shares. This addition of 720,022 shares marks a 119% increase in holdings. The total value of ARK's position in GeneDx is now about $80.3 million, indicating robust interest in the company's future.

Other Institutional Activity in GeneDx Holdings

Several other institutional investors have also adjusted their positions in GeneDx Holdings. Corvex Management LP grew its holdings by 169,520 shares, ending with 3,228,149 shares valued at approximately $207.3 million. Meanwhile, Casdin Capital, LLC maintained its position with 3,007,164 shares worth $193.1 million. BlackRock, Inc. slightly reduced its holdings by 9,386 shares, resulting in a total of 1,550,708 shares valued at $99.6 million. Westfield Capital Management Co LP added 350,847 shares, bringing its total to 1,369,108 shares worth around $87.9 million. Goldman Sachs Group Inc increased its holdings by 114,478 shares to 1,334,980 shares, valued at $85.7 million.

GeneDx Holdings Corp. Stock Up 4.6%

Shares of GeneDx Holdings Corp. (NasdaqGS: WGS) traded near $60.60. The company has a market cap of $1.8 billion, with a forward P/E ratio of 49.2 and a beta of 1.97. Over the past 52 weeks, the stock has ranged from $32.21 to $170.87. Its 50-day moving average is $55.13, while the 200-day moving average stands at $100.13. GeneDx maintains a strong current ratio of 3.09 and a quick ratio of 2.83, with a debt-to-equity ratio of 66.19.

Recent Earnings

GeneDx Holdings reported revenue of $442.7 million, reflecting a growth rate of 17.4%. However, the company posted a negative net margin of 17.6% and a return on equity of -30.4%. The next earnings report is expected on July 28, 2026.

Insider Buying and Selling at GeneDx Holdings Corp.

On June 9, 2026, GeneDx's CEO Katherine Stueland and CFO Kevin Feeley were active in trading their company's stock. Stueland bought 6,546 shares, while also selling 6,546 shares, at undisclosed prices. Feeley sold 1,266 shares at an average price of $53.77 and bought 2,462 shares at undisclosed prices.

Analysts Set New Price Targets

On May 5, 2026, Canaccord Genuity, Wells Fargo, and Guggenheim all maintained their 'buy' ratings for GeneDx Holdings, setting price targets of $75, $75, and $70, respectively. BTIG also maintained a 'buy' rating, with a target of $90. Overall, the consensus among analysts is a 'strong buy', with a mean target price of $77 based on nine opinions.

About GeneDx Holdings Corp.

GeneDx Holdings Corp. is a genomics company specializing in genetic testing services. It focuses on pediatric and rare disease diagnostics, offering whole exome and genome sequencing services. The company also develops AI-based platforms for sequencing analysis and clinical reporting, particularly in rare diseases, hereditary risks, and cancer testing. Founded in 2000, GeneDx is headquartered in Stamford, Connecticut, and employs about 1,300 people under the leadership of CEO Katherine A. Stueland.

Bottom Line

ARK Investment Management's significant increase in shares of GeneDx Holdings Corp. highlights a strong belief in the company's future. Investors often track such institutional moves to gauge potential market trends. It's important to remember that 13F filings reflect past positions and may not represent current holdings.